Precisely, MTHFR could act as blockbuster biomarker for ipilimumab therapy (AUC = 0.9) and top-quality cancer biomarker for nivolumab therapy (AUC = 0.712) to melanoma patients. This evidence concerns the gene MTHFR and melanoma.